{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:01:10Z","timestamp":1792342870300,"version":"4.4.0"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec id=\"ab-eoi230077-4\"><jats:title>Importance<\/jats:title><jats:p>Age-related macular degeneration (AMD) is a serious and common ophthalmologic disorder that is hypothesized to result, in part, from inflammatory reactions in the macula. Alzheimer disease (AD) treatment, acetylcholinesterase inhibitors (AChEIs), have anti-inflammatory effects and it remains unclear if they modify the risk of AMD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230077-5\"><jats:title>Objective<\/jats:title><jats:p>To investigate the association between AChEI medications and the incidence of AMD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230077-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This propensity score\u2013matched retrospective cohort study took place at health care facilities within the US Department of Veterans Affairs (VA) health care system from January 2000 through September 2023. Participants included patients diagnosed with AD between ages 55 and 80 years with no preexisting diagnosis of AMD in the VA database.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230077-7\"><jats:title>Exposure<\/jats:title><jats:p>AChEIs prescription dispensed as pharmacologic treatments for AD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230077-8\"><jats:title>Main Outcomes and Measure<\/jats:title><jats:p>The first diagnosis of AMD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230077-9\"><jats:title>Results<\/jats:title><jats:p>A total of 21\u202f823 veterans with AD (mean [SD] age, 72.3 [6.1] years; 21\u202f313 male participants [97.7%] and 510 female participants [2.3%]) were included. Propensity score\u2013matched Cox model reveals each additional year of AChEI treatment was associated with a 6% lower hazard of AMD (hazard ratio, 0.94; 95% CI, (0.89-0.99).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi230077-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This observational study reports a small reduction in the risk of AMD among veterans with AD receiving AChEIs. Randomized clinical trials would be needed to determine if there is a cause-and-effect relationship and further research is required to validate these findings across diverse populations.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2023.6014","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T16:32:17Z","timestamp":1704385937000},"page":"108","source":"Crossref","is-referenced-by-count":18,"title":["Alzheimer Disease Treatment With Acetylcholinesterase Inhibitors and Incident Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"142","author":[{"given":"S. Scott","family":"Sutton","sequence":"first","affiliation":[{"name":"Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina"},{"name":"Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Magagnoli","sequence":"additional","affiliation":[{"name":"Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina"},{"name":"Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy H.","family":"Cummings","sequence":"additional","affiliation":[{"name":"Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina"},{"name":"Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[{"name":"Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina"},{"name":"Department of Epidemiology & Biostatistics, University of South Carolina, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakrishna","family":"Ambati","sequence":"additional","affiliation":[{"name":"Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville"},{"name":"Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville"},{"name":"Department of Pathology, University of Virginia School of Medicine, Charlottesville"},{"name":"Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"eoi230077r1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","article-title":"Alzheimer\u2019s disease: epidemiology and clinical progression.","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"eoi230077r2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.937486","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2019.","volume":"14","author":"Li","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"eoi230077r3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and future treatments in Alzheimer\u2019s disease.","volume":"39","author":"Atri","year":"2019","journal-title":"Semin Neurol"},{"issue":"7","key":"eoi230077r4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jalz.2018.02.011","article-title":"Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia.","volume":"14","author":"Tan","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"33","key":"eoi230077r5","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","article-title":"The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer\u2019s disease.","volume":"34","author":"Nordstr\u00f6m","year":"2013","journal-title":"Eur Heart J"},{"issue":"1","key":"eoi230077r6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.kint.2022.09.022","article-title":"Association between cholinesterase inhibitors and kidney function decline in patients with Alzheimer\u2019s dementia.","volume":"103","author":"Xu","year":"2023","journal-title":"Kidney Int"},{"key":"eoi230077r7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250440","article-title":"Increased risk of Alzheimer\u2019s disease among patients with age-related macular degeneration: a nationwide population-based study.","author":"Wen","year":"2021","journal-title":"PLOS ONE"},{"issue":"12","key":"eoi230077r8","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1002\/alz.v18.12","article-title":"Lack of bidirectional association between age-related macular degeneration and Alzheimer\u2019s disease: a Mendelian randomization study.","volume":"18","author":"Jiang","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"eoi230077r9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1326-3-16","article-title":"Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin.","volume":"3","author":"Shin","year":"2008","journal-title":"Mol Neurodegener"},{"issue":"2","key":"eoi230077r10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1172\/JCI25843","article-title":"Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers.","volume":"116","author":"Luibl","year":"2006","journal-title":"J Clin Invest"},{"issue":"3","key":"eoi230077r11","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1167\/iovs.09-4207","article-title":"Soluble and mature amyloid fibrils in drusen deposits.","volume":"51","author":"Isas","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"eoi230077r12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.exer.2014.10.012","article-title":"Iron increases APP translation and amyloid-\u00df production in the retina.","volume":"129","author":"Guo","year":"2014","journal-title":"Exp Eye Res"},{"issue":"4","key":"eoi230077r13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.preteyeres.2011.02.004","article-title":"Parallel findings in age-related macular degeneration and Alzheimer\u2019s disease.","volume":"30","author":"Ohno-Matsui","year":"2011","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"eoi230077r14","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00415-018-9028-z","article-title":"Ocular amyloid imaging at the crossroad of Alzheimer\u2019s disease and age-related macular degeneration: implications for diagnosis and therapy.","volume":"266","author":"Ong","year":"2019","journal-title":"J Neurol"},{"key":"eoi230077r15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03397-2","article-title":"Amyloid \u00df peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice.","author":"Prasad","year":"2017","journal-title":"Sci Rep"},{"key":"eoi230077r16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00537-z","article-title":"Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-\u00df induced retinal pigmented epithelium degeneration.","author":"Narendran","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"eoi230077r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101954","article-title":"The central role of the NLRP3 inflammasome pathway in the pathogenesis of age-related diseases in the eye and the brain.","volume":"88","author":"Maran","year":"2023","journal-title":"Ageing Res Rev"},{"key":"eoi230077r18","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10655","article-title":"NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration.","author":"Tseng","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"eoi230077r19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0039-6257(00)00140-5","article-title":"The role of oxidative stress in the pathogenesis of age-related macular degeneration.","volume":"45","author":"Beatty","year":"2000","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"eoi230077r20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ajo.2008.05.017","article-title":"The pathogenesis of age-related macular degeneration.","volume":"146","author":"Friedman","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi230077r21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2012.03.036","article-title":"DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88.","volume":"149","author":"Tarallo","year":"2012","journal-title":"Cell"},{"issue":"41","key":"eoi230077r22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102975118","article-title":"Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration.","volume":"118","author":"Ambati","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"eoi230077r23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ana.v57:5","article-title":"Acetylcholinesterase inhibitors reduce brain and blood interleukin-1\u00df production.","volume":"57","author":"Pollak","year":"2005","journal-title":"Ann Neurol"},{"issue":"3","key":"eoi230077r24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.exger.2004.12.003","article-title":"Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer\u2019s disease patients.","volume":"40","author":"Reale","year":"2005","journal-title":"Exp Gerontol"},{"issue":"1-2","key":"eoi230077r25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jneuroim.2003.11.003","article-title":"Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines.","volume":"148","author":"Reale","year":"2004","journal-title":"J Neuroimmunol"},{"issue":"2","key":"eoi230077r26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/JCP.0000000000000840","article-title":"Acetyl cholinesterase inhibitors and cell-derived peripheral inflammatory cytokines in early stages of Alzheimer\u2019s disease.","volume":"38","author":"Kokras","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"eoi230077r27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910637","article-title":"Donepezil regulates LPS and A\u00df-stimulated neuroinflammation through MAPK\/NLRP3 inflammasome\/STAT3 signaling.","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"eoi230077r28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jneuroim.2008.06.018","article-title":"Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine.","volume":"203","author":"Nizri","year":"2008","journal-title":"J Neuroimmunol"},{"key":"eoi230077r29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lfs.2018.09.046","article-title":"Paroxetine and rivastigmine mitigates adjuvant-induced rheumatoid arthritis in rats: impact on oxidative stress, apoptosis and RANKL\/OPG signals.","volume":"212","author":"Shafiey","year":"2018","journal-title":"Life Sci"},{"issue":"2","key":"eoi230077r30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057668","article-title":"Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses.","volume":"8","author":"Shifrin","year":"2013","journal-title":"PLoS One"},{"key":"eoi230077r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109492","article-title":"Rivastigmine ameliorates gentamicin experimentally induced acute renal toxicity.","volume":"114","author":"Abdelzaher","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"eoi230077r32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93340","article-title":"Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial.","author":"Consolim-Colombo","year":"2017","journal-title":"JCI Insight"},{"issue":"7-8","key":"eoi230077r33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2119\/molmed.2011.00083","article-title":"Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice.","volume":"17","author":"Satapathy","year":"2011","journal-title":"Mol Med"},{"key":"eoi230077r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113665","article-title":"The role of a7nAChR in controlling the anti-inflammatory\/anti-arthritic action of galantamine.","volume":"170","author":"Gowayed","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"eoi230077r35","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1167\/iovs.12-11481","article-title":"Acetylcholinesterase inhibition promotes retinal vasoprotection and increases ocular blood flow in experimental glaucoma.","volume":"54","author":"Almasieh","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"eoi230077r36","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.3390\/ijms15069809","article-title":"Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity.","volume":"15","author":"Pohanka","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"5","key":"eoi230077r37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.neuropharm.2005.10.013","article-title":"Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors.","volume":"50","author":"Nizri","year":"2006","journal-title":"Neuropharmacology"},{"issue":"5","key":"eoi230077r38","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/ana.v57:5","article-title":"Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production.","volume":"57","author":"Pollak","year":"2005","journal-title":"Ann Neurol"},{"issue":"7","key":"eoi230077r39","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.neuropharm.2010.02.003","article-title":"Microglia signaling as a target of donepezil.","volume":"58","author":"Hwang","year":"2010","journal-title":"Neuropharmacology"},{"key":"eoi230077r40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejphar.2016.06.053","article-title":"Donepezil, an acetylcholinesterase inhibitor, attenuates LPS-induced inflammatory response in murine macrophage cell line RAW 264.7 through inhibition of nuclear factor kappa B translocation.","volume":"789","author":"Arikawa","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"eoi230077r41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbi.2008.06.011","article-title":"Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway.","volume":"23","author":"Pavlov","year":"2009","journal-title":"Brain Behav Immun"},{"issue":"3","key":"eoi230077r42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/01.jcp.0000125683.74595.2f","article-title":"Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells.","volume":"24","author":"Gambi","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"eoi230077r43","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.neuropharm.2005.11.006","article-title":"The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer\u2019s disease patients.","volume":"50","author":"Reale","year":"2006","journal-title":"Neuropharmacology"},{"issue":"1","key":"eoi230077r44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaophthalmol.2022.4602","article-title":"Associations of Alzheimer disease\u2013protective APOE variants with age-related macular degeneration.","volume":"141","author":"Rasmussen","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"eoi230077r45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1009977","article-title":"A locus at 19q13.31 significantly reduces the ApoE e4 risk for Alzheimer\u2019s disease in African ancestry.","volume":"18","author":"Rajabli","year":"2022","journal-title":"PLoS Genet"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2813353\/jamaophthalmology_sutton_2024_oi_230077_1707339349.93438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:01:54Z","timestamp":1708012914000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2813353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.6014","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}